Johnson and Johnson vaccine: How effective is one dose Johnson & Johnson vaccine?

Matt Hancock hails ‘good news’ on the Janssen COVID-19 vaccine

Johnson & Johnson has joined the growing crop of companies which have announced successful Covid vaccine candidates. The medical device firm is the second in two days, following Novavax, to announce an effective vaccine. But the Janssen jab has a selection of different efficacy rates and unique delivery requirements.

How effective is the Johnson & Johnson vaccine?

Johnson & Johnson returned an interim analysis of phase three clinical trials earlier today.

The trials – the final in vaccine development schedules – returned three different efficacy values.

US-based trials found the jab was 75 percent effective.

We will use your email address only for sending you newsletters. Please see our Privacy Notice for details of your data protection rights.

But it was 66 percent effective overall at preventing “moderate to severe” Covid infection 28 days after injection.

The jab is also 85 percent effective at “preventing severe disease”.

As of Day 28, injection also offered “complete protection” from Covid-19 hospitalisation and death.

The vaccine also had an impact on Covid variants, notably the South African B.1.351 version.

While some of these values aren’t quite as impressive as other jabs currently in use, the Jenssen vaccine requires only one dose.

People receiving the Pfizer, Moderna and AstraZeneca jabs need two shots spaced weeks apart.

A single shot jab would allow national authorities to better work towards herd immunity.

For example, the British Government has provided eight million first jabs in the UK, but far fewer second doses.

DON’T MISS
COVID-19: New vaccine ‘extra weapon’ against contagious strain – ANALYSIS
EU goes quiet on jab developer it gave £70m to before AstraZeneca row – INSIGHT
Novavax vaccine: Which country made the Novavax vaccine? – EXPLAINER

Single doses of already available vaccines provide roughly 60 percent protection, while a second tops it up to 90 percent or more.

Doctor Paul Stoffels, Vice Chairman of the Executive Committee and Chief Scientific Officer for Johnson & Johnson, said the early results would provide a “critical component” of public health response to the virus.

He added a single-dose vaccine fits in with World Health Organisation (WHO) guidelines.

Dr Stoffels said: “These topline results with a single-shot COVID-19 vaccine candidate represent a promising moment.”

“The potential to significantly reduce the burden of severe disease, by providing an effective and well-tolerated vaccine with just one immunisation, is a critical component of the global public health response.

“A one-shot vaccine is considered by the World Health Organisation to be the best option in pandemic settings, enhancing access, distribution and compliance.

“Eighty-five percent efficacy in preventing severe COVID-19 disease and prevention of COVID-19-related medical interventions will potentially protect hundreds of millions of people from serious and fatal outcomes of COVID-19.

“It also offers the hope of helping ease the huge burden placed on healthcare systems and communities.”

Source: Read Full Article